MIT Biotechnology Group

MBG seminar Oct 10, 4:30, 4-231

(back at the usual time)

MBG Presents the Drug Discovery Fall Seminar Series: “The Biotechnology Edge”

Dr. Dinah Sah (former Chief Scientific Officer, Voyager Therapeutics)

Preclinical Development – The Path to an IND

The Path to an Investigational New Drug (IND) Application

During a new drug’s early preclinical development, the company’s primary goal is to determine if the product is reasonably safe for initial use in humans, and if the compound exhibits pharmacological activity that justifies commercial development. When a product is identified as a viable candidate for further development, the company then focuses on collecting the data and information necessary to establish that the product will not expose humans to unreasonable risks when used in limited, early-stage clinical studies. Follow us on the path to an Investigational New Drug (IND) application. 

Please RSVP HERE to help us plan. Refreshments will be provided.

Thursday, October 10, 4:30-5:30 in room 4-231.

More information about the series HERE

Leave a Reply